ArticleAntimicrobial agents and chemotherapy2018
Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- A deformylase inhibitor expands therapeutic options for Lyme disease.Research square · 2026Article
- Fipronil prevents transmission of Lyme disease spirochetes.Parasitology · 2024Article
- Article
- Evaluation of the clinical relevance of vancomycin for the treatment of Lyme disease.Wiener klinische Wochenschrift · 2023Article
- Bacterial metabolism and susceptibility to cell wall-active antibiotics.Advances in microbial physiology · 2023Review
- Lyme disease and the pursuit of a clinical cure.Frontiers in medicine · 2023Review
- Persistent Borrelia burgdorferiClinical microbiology reviews · 2022Review
- Identification of amino acid domains ofFrontiers in cellular and infection microbiology · 2022Article
- A selective antibiotic for Lyme disease.Cell · 2021Article
- Genetic Background Amplifies the Effect of Immunodeficiency in Antibiotic Efficacy Against Borrelia burgdorferi.The Journal of infectious diseases · 2021Article
- Understanding tolerance to cell wall-active antibiotics.Annals of the New York Academy of Sciences · 2021Review
- Borrelia peptidoglycan interacting Protein (BpiP) contributes to the fitness of Borrelia burgdorferi against host-derived factors and influences virulence in mouse models of Lyme disease.PLoS pathogens · 2021Article
- Recent Progress in Lyme Disease and Remaining Challenges.Frontiers in medicine · 2021Review
- Antibiotic tolerance.PLoS pathogens · 2020Article
- Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31.Scientific reports · 2020Article
- Post-treatment Lyme Disease as a Model for Persistent Symptoms in Lyme Disease.Frontiers in medicine · 2020Review
- Generality of Post-Antimicrobial Treatment Persistence ofInfection and immunity · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.